With this cooperation, Kemwell and Boehringer Ingelheim will provide customers with technology from Europe along with the benefit of low cost manufacturing from India.
Process technology will originate from Boehringer Ingelheim and equipments in upstream and downstream in the new facility will comply with Boehringer Ingelheim’s manufacturing technology. This will ensure technology transfer and scale-up between Kemwell’s small scale and Boehringer Ingelheim’s large scale manufacturing facility to reduce time to market for the customer.
The new Kemwell Biopharma facility will be designed for process development, production, purification and formulation of biologics for early-phase preclinical and clinical studies. The facility will consist of a cGMP drug substance manufacturing facility and a sterile fill and finish facility for drug product with a floor for process development laboratories to support production of protein therapeutics from mammalian-cell culture or microbial fermentation.